Magnesium and lidocaine composition

Abstract

Embodiments include a method for treating mania which includes bolusing at least one dose to a patient of a composition which comprises magnesium and lidocaine; determining whether the patient indicates a warm feeling in response to bolusing the at least one dose of the composition; waiting for the patient to indicate that the warm feeling has gone away in response to the patient indicating the warm feeling; and verifying that the mania is reduced to a predetermined level in response to waiting for the patient to indicate that the warm feeling has gone away.

Description

MAGNESIUM AND LIDOCAINE COMPOSITIONBACKGROUND

[0001] The present invention generally relates to a composition including magnesium and lidocaine. In particular, embodiments of the present invention specifically relate to a method for delivering the composition including magnesium and lidocaine for treating pain, acute psychosis, and mania.SUMMARY

[0002] In an aspect of the present invention, a method for treating mania includes bolusing at least one dose to a patient of a composition which comprises magnesium and lidocaine; determining whether the patient indicates a warm feeling in response to bolusing the at least one dose of the composition; waiting for the patient to indicate that the warm feeling has gone away in response to the patient indicating the warm feeling; and verifying that the mania is reduced to a predetermined level in response to waiting for the patient to indicate that the warm feeling has gone away.

[0003] In further aspects of the present invention, a method for treating pain includes bolusing at least one does to a patient of a composition which comprises magnesium and lidocaine; determining whether the patient indicates a warm feeling in response to bolstering the at least one dose of the composition; waiting for the patient to indicate that the warm feeling has gone away in response to the patient indicating the warm feeling; and verifying that the pain is reduced to a predetermined level in response to waiting for the patient to indicate that the warm feeling has gone away.

[0004] In a further aspect of the present invention, a method for treating pain includes infusing a dose to a patient of a composition which comprises magnesium and lidocaine; determining whether the patient has a central nervous system (CNS) symptom based on the infused dose of the composition; waiting for the CNS symptom to resolve in response to the patient having the CNS symptom based on the infused dose of the composition; and verifying that the pain is reduced to a predetermined level in response to the patient not having the CNS symptom based on the infused dose of the composition

[0005] In another aspect of the present invention, a method for treating mania includes infusing a dose to a patient of a composition which comprises magnesium and lidocaine; determining whether the patient has a central nervous system (CNS) symptom based on the infused dose of the composition; waiting for the CNS symptom to resolve in response to the patient having the CNS symptom based on the infused dose of the composition; and verifying that the mania is reduced to a predetermined level in response to the patient not having the CNS symptom based on the infused dose of the composition.BRIEF DESCRIPTION OF THE DRAWINGS

[0006] The present invention is described in the detailed description which follows, in reference to the noted plurality of drawings by way of non-limiting examples of exemplary embodiments of the present invention.

[0007] FIG. 1 shows a flowchart of administering a first composition for pain including magnesium and lidocaine in accordance with aspects of the invention.

[0008] FIG. 2 shows another flowchart of administering a first composition for pain includingmagnesium and lidocaine in accordance with aspects of the present invention.

[0009] FIG. 3 shows another flowchart of administering a first composition for acute psychosis and mania including magnesium and lidocaine in accordance with aspects of the present invention.

[0010] FIG. 4 shows another flowchart of administering a first composition for acute psychosis and mania including magnesium and lidocaine in accordance with aspects of the present invention.

[0011] FIG. 5 shows another flowchart of administering a second composition for acute psychosis and mania including magnesium and lidocaine in accordance with aspects of the present invention.

[0012] FIG. 6 shows another flowchart of administering a second composition for pain including magnesium and lidocaine in accordance with aspects of the present invention.

[0013] FIG. 7 shows a table of compositions to address pain management in accordance with aspects of the present invention.

[0014] FIG. 8 shows a table of compositions to address acute psychosis and mania compositions in accordance with aspects of the present invention.DETAILED DESCRIPTION

[0015] The present invention generally relates to a composition including magnesium and lidocaine. In particular, embodiments of the present invention specifically relate to a method for delivering the composition including magnesium and lidocaine for treating pain and acutepsychosis and mania. In an example, mania may include a loss of appetite, poor sleep, pressure speech, and manic episodes.

[0016] When spinal neurons are subject to repeated or high-intensity nociceptive impulses, the spinal neurons on progressively and increasingly excitable even after a stimulus is removed. This condition is known as a central sensitization or a wind-up phenomenon and leads to nonresponsive or chronic intractable pain that is resistant to powerful pain medications. Further, a similar cellular response also plays a role in psychiatric conditions such as acute psychosis and mania.

[0017] In embodiments of the present invention, a composition including magnesium and lidocaine reverses the wind-up phenomenon by placing magnesium intracellular and allowing the magnesium to bind to a receptor site and reversing the wind-up phenomenon. However, simply administering magnesium does not reverse the wind-up phenomenon, treat pain, or treat acute psychosis and mania. Further, simply administering lidocaine does not treat chronic and intractable pain, acute psychosis, and mania. In aspects of the present invention, the composition including both magnesium and lidocaine is a key to effective treatment of pain, acute psychosis, and mania.

[0018] In accordance with aspects of the present invention, there is provided a first composition for treating pain, acute psychosis, and mania which includes:1) 2 mg of Magnesium in water; and2) 200 mg of preservative free 2% Lidocaine.

[0019] In embodiments of the present invention, the first composition is bolused in four doses.In further embodiments of the present invention, bolusing the first composition in four doses creates a high plasma level. In an aspect of the present invention, when the first composition is bolused in four doses, a warm sensation is created in a body of a patient. During administration of the first composition by bolusing, a patient indicates a feeling of the warm sensation or any symptoms of lidocaine toxicity (e.g., metallic taste, ringing in the cars, etc.) and also indicates when the warm sensation or the symptoms of lidocaine toxicity goes away. If the first composition is administered without waiting for any symptoms of lidocaine toxicity to resolve, the lidocaine in the first composition may cause seizures and cardiac arrests at toxic doses. Waiting for the warm sensation to go away in the previous doses improves the tolerability of the warmth from the subsequent boluses and eliminates the risk of lidocaine toxicity. Accordingly, by bolusing the first composition over a first dosage, waiting for the patient to indicate that the warming sensation goes away, bolusing the first composition over a second dosage, waiting for the patient to indicate that the warming sensation goes away, bolusing the first composition over a third dosage, waiting for the patient to indicate that the warming sensation goes away, and bolusing the first composition over a fourth dosage, seizures and cardiac arrests in the patient can be avoided. In an example, the bolusing of the first composition is administered by dividing the first composition into four equal syringes (i.e., each syringe has 1 / 4 of the total amount of the first composition) and bolusing one syringe at a time to the patient during each dose. In further embodiments, the first composition includes the 2 mg of Magnesium in 50 ml of sterile water with 200 mg of preservative free 2% Lidocaine. In an example, by administering the first composition, severe pain can be reduced by up to 66%.

[0020] In further embodiments, the bolusing of the first composition may be administered inless than four doses by carefully managing and discussing with the patient central nervous system (CNS) symptoms and lidocaine toxicity which are a precursor to seizures and cardiac arrests. Also, in further embodiments, the bolusing of the first composition may be administered in greater than four doses to further enhance the safety profile and avoid seizures and cardiac arrests due to lidocaine toxicity.

[0021] In further embodiments of the present invention, during administration of the first composition by bolusing, a patient indicates when a CNS symptom occurs, such as a metallic taste in a mouth, ringing in the ears, etc. If the first composition is administered without determining whether the patient has a CNS symptom, such as a metallic taste in a mouth, the lidocaine in the first composition may cause seizures and cardiac arrests at toxic doses. Accordingly, by bolusing the first composition over multiple doses (e.g., four doses), seizures and cardiac arrests in the patient due to CNS symptoms can be avoided.

[0022] In accordance with aspects of the present invention, there is provided a second composition for treating pain, acute psychosis, and mania which includes:1) 2 mg of Magnesium in water; and2) 100 mg of preservative free 2% Lidocaine.

[0023] In embodiments of the present invention, the first composition is infused over ten minutes to the patient in a single syringe. In further embodiments of the present invention, the second composition is typically used when the patient is mentally impaired (e.g., schizophrenia, acute psychosis, mania, dementia, Alzheimer, etc.) or has difficulty in communicating a feeling of the warm sensation or CNS symptoms. Accordingly, by infusing the second compositionover ten minutes with a lower concentration of lidocaine, the safety profile is enhanced to avoid seizures and cardiac arrests due to lidocaine toxicity. In further embodiments, the second composition includes the 2 mg of Magnesium in 50 ml of sterile water with 100 mg of preservative free 2% Lidocaine. By administering the second composition in a single syringe once every day for three days, the appetite of the patient returned during day one, the patient was able to sleep six to eight hours a night during day two, and all mania symptoms were gone after three days.

[0024] In further embodiments, the infusing of the second composition may be administered in greater than ten minutes to further enhance the safety profile and avoid seizures and cardiac arrests due to lidocaine toxicity. In other embodiments, the infusing of the second composition may be administered in less than ten minutes as long as the safety profile is maintained to avoid seizures and cardiac arrests due to lidocaine toxicity.

[0025] In embodiments of the present invention, by administering the first composition or the second composition to a patient, there is no need for a non-steroidal anti-inflammatory drug (NSAID), such as ketorolac. Although ketorolac is a powerful pain medication, ketorolac (and other NSAIDs) can cause bleeding and kidney damage. However, in aspects of the present invention, the first composition and the first composition accomplishes the same benefits of a power pain medication as NSAIDs without the risk of bleeding and kidney damage.

[0026] In aspects of the present invention, the first composition and the second composition can be administered to a patient using at least one drug delivery process including intravenous, intramuscular, a gel, subcutaneous, inhalation, intra-articular, transdermal patches, orally (e.g., liquid, tablet, etc.), sublingual, intrathecal, etc. However, embodiments of the present inventionare not limited to the above drug delivery processes, and can utilize other drug delivery processes for the first composition and the second composition.

[0027] FIG. 1 shows a flowchart of administering a first composition including magnesium and lidocaine for pain in accordance with aspects of the invention. At step 100, a patient who has a high level of pain is administered a first composition which includes magnesium and lidocaine by bolusing a first dose of the first composition to the patient. At step 105, during bolusing the first dose of the first composition, the patient is asked whether a warm feeling has been felt. At step 110, in response to the patient indicating a warm feeling, the patient does not receive a bolused second dose until the patient indicates that the warm feeling has gone away. Then, at step 115, the patient is administered the first composition by bolusing a second dose of the first composition to the patient. In further embodiments, at step 115, the patient is administered the first composition by bolusing the second dose of the first composition in response to the patient not indicating the warm feeling being felt.

[0028] In further embodiments of FIG. 1, at step 120, during bolusing the second dose of the first composition, the patient is asked whether the warm feeling has been felt. At step 125, in response to the patient indicating the warm feeling, the patient does not receive the bolused second dose until the patient indicates that the warm feeling has gone away. Then, at step 130, the patient is administered the first composition by bolusing a third dose of the first composition to the patient. In further embodiments, at step 130, the patient is administered the first composition by bolusing the third dose of the first composition in response to the patient not indicating the warm feeling being felt.

[0029] In aspects of the present invention in FIG. 1, at step 135, during bolusing the third doseof the first composition, the patient is asked whether the warm feeling has been felt. At step140, in response to the patient indicating the warm feeling, the patient does not receive the bolused fourth dose until the patient indicates that the warm feeling has gone away. Then, at step 145, the patient is administered the first composition by bolusing a fourth third dose of the first composition to the patient. In further embodiments, at step 145, the patient is administered the first composition by bolusing the fourth dose of the first composition in response to the patient not indicating the warm feeling being felt. Lastly, at step 150, the patient verifies that the pain is reduced to a manageable level as a result of the bolusing of the first composition in four doses.F0030] FIG. 2 shows another flowchart of administering a first composition including magnesium and lidocaine for pain in accordance with aspects of the invention. At step 200, a patient who has a high level of pain is administered a first composition which includes magnesium and lidocaine by bolusing a first dose of the first composition to the patient. At step 205, during bolusing the first dose of the first composition, the patient is asked whether there is an indication of a central nervous symptom (e.g., metallic taste in a mouth of the patient). At step 210, in response to the patient indicating CNS symptoms, the patient indicates when the CNS symptoms go away and then the flowchart goes to step 215. In further embodiments, at step 215, the patient is administered the first composition by bolusing the second dose of the first composition in response to the patient not indicating CNS symptoms.

[0031] In further embodiments of FIG. 2, at step 220, during bolusing the second dose of the first composition, the patient is asked whether there is an indication of the CNS symptoms. At step 225, in response to the patient indicating CNS symptoms, the patient indicates when the CNS symptoms go away and then the flowchart goes to step 230. In further embodiments, atstep 230, the patient is administered the first composition by bolusing the third dose of the first composition in response to the patient not indicating CNS symptoms.

[0032] In aspects of the present invention in FIG. 2, at step 235, during bolusing the third dose of the first composition, the patient is asked whether there is an indication of the CNS symptoms. At step 240, in response to the patient indicating CNS symptoms, the patient indicates when the CNS symptoms go away and then the flowchart goes to step 245. In further embodiments, at step 245, the patient is administered the first composition by bolusing the fourth dose of the first composition in response to the patient not indicating CNS symptoms. Lastly, at step 250, the patient verifies that the pain is reduced to a manageable level as a result of the bolusing of the first composition in four doses.

[0033] FIG. 3 shows a flowchart of administering a first composition including magnesium and lidocaine for acute psychosis and mania in accordance with aspects of the invention. At step 300, a patient who has a high level of pain is administered a first composition which includes magnesium and lidocaine by bolusing a first dose of the first composition to the patient. At step 305, during bolusing the first dose of the first composition, the patient is asked whether a warm feeling has been felt. At step 310, in response to the patient indicating a warm feeling, the patient does not receive a bolused second dose until the patient indicates that the warm feeling has gone away. Then, at step 315, the patient is administered the first composition by bolusing a second dose of the first composition to the patient. In further embodiments, at step 315, the patient is administered the first composition by bolusing the second dose of the first composition in response to the patient not indicating the warm feeling being felt.

[0034] In further embodiments of FIG. 3, at step 320, during bolusing the second dose of thefirst composition, the patient is asked whether the warm feeling has been felt. At step 325, in response to the patient indicating the warm feeling, the patient does not receive the bolused second dose until the patient indicates that the warm feeling has gone away. Then, at step 330, the patient is administered the first composition by bolusing a third dose of the first composition to the patient. In further embodiments, at step 330, the patient is administered the first composition by bolusing the third dose of the first composition in response to the patient not indicating the warm feeling being felt.

[0035] In aspects of the present invention in FIG. 3, at step 335, during bolusing the third dose of the first composition, the patient is asked whether the warm feeling has been felt. At step 340, in response to the patient indicating the warm feeling, the patient does not receive the bolused fourth dose until the patient indicates that the warm feeling has gone away. Then, at step 345, the patient is administered the first composition by bolusing a fourth third dose of the first composition to the patient. In further embodiments, at step 345, the patient is administered the first composition by bolusing the fourth dose of the first composition in response to the patient not indicating the warm feeling being felt. Lastly, at step 350, the patient verifies that acute psychosis and mania is reduced to a manageable level as a result of the bolusing of the first composition in four doses.

[0036] FIG. 4 shows another flowchart of administering a first composition including magnesium and lidocaine for acute psychosis and mania in accordance with aspects of the invention. At step 400, a patient who has a high level of pain is administered a first composition which includes magnesium and lidocaine by bolusing a first dose of the first composition to the patient. At step 405, during bolusing the first dose of the first composition, the patient is asked whether there is an indication of a central nervous symptom (e.g., metallictaste in a mouth of the patient). At step 410, in response to the patient indicating CNS symptoms, the patient indicates when the CNS symptoms go away and then the flowchart goes to step 415. In further embodiments, at step 415, the patient is administered the first composition by bolusing the second dose of the first composition in response to the patient not indicating CNS symptoms.

[0037] In further embodiments of FIG. 4, at step 420, during bolusing the second dose of the first composition, the patient is asked whether there is an indication of the CNS symptoms. At step 425, in response to the patient indicating CNS symptoms, the patient indicates when the CNS symptoms go away and then the flowchart goes to step 430. In further embodiments, at step 430, the patient is administered the first composition by bolusing the third dose of the first composition in response to the patient not indicating CNS symptoms.

[0038] In aspects of the present invention in FIG. 4, at step 435, during bolusing the third dose of the first composition, the patient is asked whether there is an indication of the CNS symptoms. At step 440, in response to the patient indicating CNS symptoms, the patient indicates when the CNS symptoms go away and then the flowchart goes to step 445. In further embodiments, at step 445, the patient is administered the first composition by bolusing the fourth dose of the first composition in response to the patient not indicating CNS symptoms. Lastly, at step 450, the patient verifies that acute psychosis and mania is reduced to a manageable level as a result of the bolusing of the first composition in four doses.

[0039] FIG. 5 shows another flowchart of administering a second composition including magnesium and lidocaine for acute psychosis and mania in accordance with aspects of the invention. At step 500, a patient who has acute psychosis and mania is administered a secondcomposition which includes magnesium and lidocaine by infusing a single dose of the second composition to the patient. At step 505, during infusing the single dose of the second composition, there is a determination of whether the patient manifests an abnormal arrythmia or abnormal heartbeat using an electrocardiogram (EKG) machine. At step 510, in response to the patient manifesting the abnormal arrythmia or the abnormal heartbeat of the patient, the flowchart moves to step 515 after the abnormal arrythmia or the abnormal heartbeat resolves. In further embodiments, at step 515, there is a verification of whether the acute psychosis and mania is reduced to a manageable level as a result of the infusing the second composition in a single dose. In further embodiments, the administering of the second composition including magnesium and lidocaine for acute psychosis and mania can also include a determination of whether the patient manifests CNS symptoms (e.g., ringing in the ear’s, metallic taste in a mouth, etc.), waiting for the CNS symptoms to resolve, and verifying that the acute psychosis and mania is reduced to a predetermined level in response to the patient not having the CNS symptoms based on an infused dose of the second composition.

[0040] FIG. 6 shows another flowchart of administering a second composition including magnesium and lidocaine for pain in accordance with aspects of the invention. At step 600, a patient who has pain is administered a second composition which includes magnesium and lidocaine by infusing a single dose of the second composition to the patient. At step 605, during infusing the single dose of the second composition, there is a determination of whether the patient manifests an abnormal arrythmia or abnormal heartbeat using an electrocardiogram (EKG) machine. At step 610, in response to the patient manifesting the abnormal arrythmia or the abnormal heartbeat of the patient, the flowchart moves to step 615 after the abnormal arrythmia or the abnormal heartbeat resolves. In further embodiments, at step 615, there is averification of whether the pain is reduced to a manageable level as a result of the infusing the second composition in a single dose. In further embodiments, the administering of the second composition including magnesium and lidocaine for pain can also include a determination of whether the patient manifests CNS symptoms (e.g., ringing in the ears, metallic taste in a mouth, etc.), waiting for the CNS symptoms to resolve, and verifying that the pain is reduced to a predetermined level in response to the patient not having the CNS symptoms based on an infused dose of the second composition.

[0041] FIG. 7 shows a table of compositions to address pain management in accordance with aspects of the present invention. In embodiments of the present invention, a table 700 includes the first composition and the second composition of magnesium and lidocaine (i.e., mag / lidocaine) being able to treat mild to moderate pain, moderate to severe pain, and intractable pain with minimal side effects at therapeutic doses with a low potential for abuse. In contrast, administering only magnesium is not effective for treating any pain level. Further, administering only lidocaine treats mild to moderate pain, but has potential side effects of CNS symptoms, seizures, cardiac arrhythmias, etc. Administering ketorolac is able to treat mild to moderate pain and moderate to severe pain, but can have side effects of kidney damage and bleeding. Administering acetaminophen (e.g., Tylenol) is able to treat mild to moderate pain, but can have liver damage at high doses. Administering opioids can treat mild to moderate pain, moderate to severe pain, and intractable pain, but has side effects of respiratory depression and sedation and a high potential for abuse. Administering ketamine can treat mild to moderate pain, moderate to severe pain, and intractable pain, but has side effects of sedation and hallucinations and a high potential for abuse.

[0042] FIG. 8 shows a table of compositions to address acute psychosis and mania inaccordance with aspects of the present invention. In embodiments of the present invention, a table 800 includes the first composition and the second composition of magnesium and lidocaine (i.e., mag / lido) being able to treat acute psychosis and mania with minimal side effects at therapeutic doses with a low potential for abuse. In contrast, administering only antipsychotic (e.g., haloperidol) treats symptoms of agitation, but causes sedation, low blood pressure, dizziness, and dry mouth. Further, administering only benziodiazapine (e.g., Ativan, lorazepam) treats symptoms of agitation, but has potential side effects of sedation and memory loss. Administering atypical antipsychotic drugs (e.g., risperidone, clozapine) is able to treat acute psychosis and mania after 1-2 weeks after administration, but has several extrapyramidal symptoms, such as akathisia, dystonia, neurological malignant syndrome, parkinsonian, tardive dyskinesia and seizures. Administering magnesium is not able to treat acute psychosis or mania. Administering anticonvulsant (e.g., valproate, carbamazepine) treats acute psychosis and mania after 1-2 weeks after administration, but has several extrapyramidal symptoms, such as akathisia, dystonia, neurological malignant syndrome, parkinsonian, tardive dyskinesia and liver failures and thrombocytopenia. Administering a mood stabilizer (e.g., lithium) can treat acute psychosis and mania around 2 weeks after administration, but has side effects of kidney damage and toxicity risk, which requires constant monitoring of blood levels.

[0043] In embodiments, a computing device, a robot, or a drug administration device could offer to perform the processes described herein. In this case, the computing device, the robot, or the drug administration device can create, maintain, deploy, support, etc., the computer infrastructure that performs the process steps of the invention for one or more patients. These patients may be, for example, any person that has pain, acute psychosis, or mania. In return, the computing device, the robot, or the drug administration device can receive payment from thepatient under a subscription and / or fee agreement, the computing device, the robot, or the drug administration device can receive payment from the sale of advertising content to one or more third parties.

[0044] The descriptions of the various embodiments of the present invention have been presented for purposes of illustration, but are not intended to be exhaustive or limited to the embodiments disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The terminology used herein was chosen to best explain the principles of the embodiments, the practical application or technical improvement over technologies found in the marketplace, or to enable others of ordinary skill in the art to understand the embodiments disclosed herein.

Claims

CLAIMSWhat is claimed is:

1. A method for treating mania, comprising: bolusing at least one dose to a patient of a composition which comprises magnesium and lidocaine; determining whether the patient indicates a warm feeling in response to bolusing the at least one dose of the composition; waiting for the patient to indicate that the warm feeling has gone away in response to the patient indicating the warm feeling; and verifying that the mania is reduced to a predetermined level in response to waiting for the patient to indicate that the warm feeling has gone away.

2. The method of claim 1, wherein the composition further comprises:2 mg of Magnesium in 50 milliliters of sterile water; and200 mg of preservative free 2% Lidocaine.

3. The method of claim 1, wherein the bolusing the at least one dose to the patient of the composition which comprises magnesium and lidocaine further comprises: bolusing a first dose to the patient of the composition; bolusing a second dose to the patient of the composition; bolusing a third dose to the patient of the composition; and bolusing a fourth dose to the patient of the composition.

4. The method of claim 3, wherein each of the first dose, the second dose, the third dose, and the fourth dose comprise equal amounts of the composition.

5. The method of claim 4, wherein the waiting for the patient to indicate that the warm feeling has gone away in response to the patient indicating the warm feeling further comprises: waiting for the patient to indicate that the warm feeling has gone away after the first dose in response to the patient indicating the warm feeling has gone away; waiting for the patient to indicate that the warm feeling has gone away after the second dose in response to the patient indicating the warm feeling has gone away; and waiting for the patient to indicate that the warm feeling has gone away after the third dose in response to the patient indicating the warm feeling has gone away.

6. The method of claim 1, further comprising verifying that the mania is reduced to the predetermined level in response to the patient not having a central nervous system (CNS) symptom in response to bolusing the at least one dose of the composition.

7. A method for treating pain, comprising: bolusing at least one dose to a patient of a composition which comprises magnesium and lidocaine; determining whether the patient indicates a warm feeling in response to bolusing the at least one dose of the composition; waiting for the patient to indicate that the warm feeling has gone away in response to the patient indicating the warm feeling; andverifying that the pain is reduced to a predetermined level in response to waiting for the patient to indicate that the warm feeling has gone away.

8. The method of claim 7, wherein the composition further comprises:2 mg of Magnesium in 50 milliliters of sterile water; and200 mg of preservative free 2% Lidocaine.

9. The method of claim 7, wherein the bolusing the at least one dose to the patient of the composition which comprises magnesium and lidocaine further comprises: bolusing a first dose to the patient of the composition; bolusing a second dose to the patient of the composition; bolusing a third dose to the patient of the composition; and bolusing a fourth dose to the patient of the composition.

10. The method of claim 9, wherein each of the first dose, the second dose, the third dose, and the fourth dose comprise equal amounts of the composition.

11. The method of claim 10, wherein the determining whether the patient indicates the warm feeling in response to bolusing the at least one dose of the composition further comprises: determining whether the patient indicates the warm feeling in response to bolusing the first dose of the composition; determining whether the patient indicates the warm feeling in response to bolusing thesecond dose of the composition; and determining whether the patient indicates the warm feeling in response to bolusing the third dose of the composition.

12. The method of claim 11, wherein the waiting for the patient to indicate that the warm feeling has gone away in response to the patient indicating the warm feeling further comprises: waiting for the patient to indicate that the warm feeling has gone away after the first dose in response to the patient indicating the warm feeling has gone away; waiting for the patient to indicate that the warm feeling has gone away after the second dose in response to the patient indicating the warm feeling has gone away; and waiting for the patient to indicate that the warm feeling has gone away after the third dose in response to the patient indicating the warm feeling has gone away.

13. The method of claim 12, wherein the verifying that the pain is reduced to the predetermined level in response to waiting for the patient to indicate that the warm feeling has gone away comprises verifying that the pain is reduced to the predetermined level in response to waiting for the patient to indicate that the warm feeling has gone away after the third dose and bolusing the fourth dose to the patient of the composition.

14. The method of claim 7, wherein the pain comprises chronic intractable pain that is due to a wind-up phenomenon.

15. The method of claim 14, wherein the predetermined level is a level in which the patient is not experiencing the chronic intractable pain.

16. The method of claim 7, wherein the pain comprises moderate to severe pain, and the predetermined level is a level in which the patient is not experiencing the moderate to severe pain.

17. A method for treating pain, comprising: infusing a dose to a patient of a composition which comprises magnesium and lidocaine; determining whether the patient has a central nervous system (CNS) symptom based on the infused dose of the composition; waiting for the CNS symptom to resolve in response to the patient having the CNS symptom based on the infused dose of the composition; and verifying that the pain is reduced to a predetermined level in response to the patient not having the CNS symptom based on the infused dose of the composition.

18. A method for treating mania, comprising: infusing a dose to a patient of a composition which comprises magnesium and lidocaine; determining whether the patient has a central nervous system (CNS) symptom based on the infused dose of the composition; waiting for the CNS symptom to resolve in response to the patient having the CNSsymptom based on the infused dose of the composition; and verifying that the mania is reduced to a predetermined level in response to the patient not having the CNS symptom based on the infused dose of the composition.

19. The method of claim 18, further comprising verifying that the mania is reduced to the predetermined level in response to waiting for the CNS symptoms to resolve.

20. The method of claim 18, wherein the CNS symptoms comprises at least one of a ringing in the ears of the patient and a metallic taste in a mouth of the patient.

Images